AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Miratas 50 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Mirabegron (50mg)

Overview Miratas 50 Tablet ER

Extended-release Miratas 50mg tablets manage overactive bladder symptoms such as urinary frequency, urgency, and incontinence. This medication relaxes bladder muscles, improving urine storage capacity. Dosage and treatment length should strictly follow your doctor's instructions. It can be taken with or without food; swallow the tablet whole – do not crush or chew. Discontinuing treatment prematurely may exacerbate symptoms; complete the prescribed course for optimal results. Possible side effects include constipation, headache, hypertension, rhinitis, urinary tract infection, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your physician immediately. Before starting treatment, disclose all other medications and pre-existing health conditions, including pregnancy or breastfeeding. Patients with hepatic or renal impairment require careful monitoring and regular check-ups under medical supervision.

Uses of Miratas 50 Tablet ER

Managing symptoms associated with overactive bladder

Major Benefits of Miratas 50 Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Miratas 50 ER Tablet whole; do not alter its form. It can be taken with or without food, but consistency in timing is recommended.

Common Side effects of Miratas 50 Tablet ER:

  • Constipation
  • Headache
  • High blood pressure
  • Nasal inflammation
  • Urinary tract infection
  • Fast heart rate
  • Joint pain

How to use Miratas 50 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Miratas 50 ER tablets can be administered with or without food; however, consistent daily timing is recommended.

How Miratas 50 Tablet ER works:

Miratas 50 Extended-Release tablets contain a beta-3 adrenergic agonist. This medication's action involves stimulating bladder beta-3 receptors, resulting in bladder muscle relaxation and a reduction in urinary urgency, frequency, and incontinence.

SAFETY ADVICE

AlcoholAlcoholCAUTION

Use caution when combining Miratas 50 Tablet ER and alcohol. Physician consultation is recommended.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Miratas 50mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Prolonged-release Miratas 50mg tablets are likely unsuitable for breastfeeding mothers. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingSAFE

Driving ability is typically unaffected by Miratas 50 ER tablets.

KidneyKidneyCAUTION

For individuals with severe kidney impairment, Miratas 50 Extended-Release tablets require careful administration. Dosage modification of Miratas 50 Extended-Release tablets may be necessary. Physician consultation is advised.

LiverLiverCAUTION

Patients with hepatic impairment should exercise caution when using Miratas 50 Extended-Release tablets, as dose modification may be necessary. Individuals with severe liver disease should avoid Miratas 50 Extended-Release tablets. Physician consultation is advised.

What if you forget to take Miratas 50 Tablet ER :

Should you forget a Miratas 50 Tablet ER dose, take it immediately. However, near the time for your next dose, omit the missed one and resume your usual dosing pattern. Avoid taking a double dose.

Facts to Know About Miratas 50 Tablet ER

LabelValue
Chemical Type Anilide-based Compound
Developing Habits No.
Type of Therapy Urological Care
Action Class Beta-3 agonist for bladder control

FAQs on Miratas 50 Tablet ER

Miratas 50 Tablet ER's full effects may become apparent after eight weeks or more of treatment. Dosage adjustments may be considered after four to eight weeks, depending on individual response.
Continue taking Miratas 50 Tablet ER, even if your symptoms improve. This medication doesn't cure overactive bladder; it manages urgency, frequent urination, and incontinence. Discontinuing treatment could cause your symptoms to return.
Miratas 50 Tablet ER shouldn't interfere with your sleep. Consult your doctor about any sleep difficulties.
Miratas 50 Tablet ER should not be given to children under 18 as its safety and efficacy in this age group haven't been established.
Daily use, as prescribed, is crucial because this medication manages, not cures, your condition. Intermittent use prevents your bladder from adapting fully, leading to ineffective treatment and symptom recurrence.
Miratas 50 Tablet ER may cause urinary tract infections (kidneys, ureters, bladder, or urethra), though this is not universal. Renal stones and bladder pain are rare side effects. Patients with impaired kidney function should use caution and report any kidney-related symptoms to their doctor.
Miratas 50 Tablet ER may raise blood pressure; monitor your blood pressure regularly if you are using it, and avoid this medication if you have severe, uncontrolled hypertension.
Seek immediate medical help, regardless of symptoms. Miratas 50 Tablet ER overdose can elevate heart rate and blood pressure, potentially causing severe headache, palpitations, chest pain, and fatigue.
Miratas 50 Tablet ER
245
MRP 299
18% off